The effect of circadian rhythm on pharmacokinetics and metabolism of the Cdk inhibitor, roscovitine, in tumor mice model

REFERENCES

• Afsharian P, Terelius Y, Hassan Z, et al. (2007). The effect of repeated administration of cyclophosphamide on cytochrome P450 2B in rats. Clin Cancer Res. 13:4218–24
   PubMed Web of Science ®Google Scholar
• Aldoss IT, Tashi T, Ganti AK. (2009). Seliciclib in malignancies. Expert Opin Investig Drugs. 18:1957–65
   PubMed Web of Science ®Google Scholar
• Altinok A, Levi F, Goldbeter A. (2009). Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur J Pharm Sci. 36:20–38
   PubMed Web of Science ®Google Scholar
• Baraldo M. (2008). The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol. 4:175–92
   PubMed Web of Science ®Google Scholar
• Bellet MM, Sassone-Corsi P. (2010). Mammalian circadian clock and metabolism – The epigenetic link. J Cell Sci. 123:3837–48
   PubMed Web of Science ®Google Scholar
• Benson C, White J, De Bono J, et al. (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer. 96:29–37
   PubMed Web of Science ®Google Scholar
• Bettayeb K, Baunbaek D, Delehouze C, et al. (2010). CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer. 1:369–80
   Google Scholar
• Bettayeb K, Sallam H, Ferandin Y, et al. (2008). N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine. Mol Cancer Ther. 7:2713–24
   PubMed Web of Science ®Google Scholar
• Bukanov NO, Moreno SE, Natoli TA, et al. (2012). CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 11:4040–6
   PubMed Web of Science ®Google Scholar
• Dallmann R, Brown SA, Gachon F. (2014). Chronopharmacology: New insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 54:339–61
   PubMed Web of Science ®Google Scholar
• Daujat M, Clair P, Astier C, et al. (1991). Induction, regulation and messenger half-life of cytochromes P450 IA1, IA2 and IIIA6 in primary cultures of rabbit hepatocytes. CYP 1A1, 1A2 and 3A6 chromosome location in the rabbit and evidence that post-transcriptional control of gene IA2 does not involve mRNA stabilization. Eur J Biochem. 200:501–10
   Google Scholar
• Delehouze C, Godl K, Loaec N, et al. (2013). CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 33:5675–87
   PubMed Web of Science ®Google Scholar
• Doi M, Hirayama J, Sassone-Corsi P. (2006). Circadian regulator CLOCK is a histone acetyltransferase. Cell. 125:497–508
   PubMed Web of Science ®Google Scholar
• Eckel-Mahan K, Sassone-Corsi P. (2013a). Epigenetic regulation of the molecular clockwork. Prog Mol Biol Transl Sci. 119:29–50
   PubMed Web of Science ®Google Scholar
• Eckel-Mahan K, Sassone-Corsi P. (2013b). Metabolism and the circadian clock converge. Physiol Rev. 93:107–35
   PubMed Web of Science ®Google Scholar
• El-Serafi I, Terelius Y, Twelkmeyer B, et al. (2013). Gas chromatographic-mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 913–914:98–105
   PubMed Web of Science ®Google Scholar
• Filipski E, Delaunay F, King VM, et al. (2004). Effects of chronic jet lag on tumor progression in mice. Cancer Res. 64:7879–85
   PubMed Web of Science ®Google Scholar
• Filipski E, King VM, Li X, et al. (2003). Disruption of circadian coordination accelerates malignant growth in mice. Pathol Biol (Paris). 51:216–19
   PubMed Web of Science ®Google Scholar
• Filipski E, Lemaigre G, Liu XH, et al. (2004). Circadian rhythm of irinotecan tolerability in mice. Chronobiol Int. 21:613–30
   PubMed Web of Science ®Google Scholar
• Filipski E, Li XM, Levi F. (2006). Disruption of circadian coordination and malignant growth. Cancer Causes Control. 17:509–14
   PubMed Web of Science ®Google Scholar
• Gachon F, Olela FF, Schaad O, et al. (2006). The circadian PAR-domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 4:25–36
   PubMed Web of Science ®Google Scholar
• Gholam D, Giacchetti S, Brezault-Bonnet C, et al. (2006). Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist. 11:1072–80
   PubMed Web of Science ®Google Scholar
• Innominato PF, Focan C, Gorlia T, et al. (2009). Circadian rhythm in rest and activity: A biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700–7
   PubMed Web of Science ®Google Scholar
• Iurisci I, Filipski E, Reinhardt J, et al. (2006). Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 66:10720–8
   PubMed Web of Science ®Google Scholar
• Iurisci I, Filipski E, Sallam H, et al. (2009). Liver circadian clock, apharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int. 26:e1169–88
   PubMed Web of Science ®Google Scholar
• Janich P, Toufighi K, Solanas G, et al. (2013). Human epidermal stem cell function is regulated by circadian oscillations. Cell Stem Cell. 13:745–53
   PubMed Web of Science ®Google Scholar
• Knockaert M, Greengard P, Meijer L. (2002). Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 23:417–25
   PubMed Web of Science ®Google Scholar
• Lambert LA, Qiao N, Hunt KK, et al. (2008). Autophagy: A novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 68:7966–74
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Faivre S, Laurence V, et al. (2010). Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer. 46:3243–50
   PubMed Web of Science ®Google Scholar
• Levi F, Okyar A, Dulong S, et al. (2010). Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 50:377–421
   PubMed Web of Science ®Google Scholar
• Levi F, Schibler U. (2007). Circadian rhythms: Mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 47:593–628
   PubMed Web of Science ®Google Scholar
• Levi FA. (2008). The circadian timing system: A coordinator of life processes: Chronobiological investigations. Implications for the rhythmic delivery of cancer therapeutics. IEEE Eng Med Biol Mag. 27:17–19
   PubMed Web of Science ®Google Scholar
• Lin JH, Lu AY. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev. 49:403–49
   PubMed Web of Science ®Google Scholar
• Lofgren S, Baldwin RM, Hiratsuka M, et al. (2008). Generation of mice transgenic for human CYP2C18 and CYP2C19: Characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos. 36:955–62
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–75
   PubMed Web of Science ®Google Scholar
• McClue SJ, Stuart I. (2008). Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (R-roscovitine) in vitro and in vivo. Drug Metab Dispos. 36:561–70
   PubMed Web of Science ®Google Scholar
• Meijer L, Raymond E. (2003). Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res. 36:417–25
   Google Scholar
• Mormont MC, Levi F. (2003). Cancer chronotherapy: Principles, applications, and perspectives. Cancer. 97:155–69
   PubMed Web of Science ®Google Scholar
• Ohdo S. (2007). Chronopharmacology focused on biological clock. Drug Metab Pharmacokinet. 22:3–14
   PubMed Web of Science ®Google Scholar
• Ohdo S, Koyanagi S, Matsunaga N. (2010). Chronopharmacological strategies: Intra- and inter-individual variability of molecular clock. Adv Drug Deliv Rev. 62:885–97
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, et al. (2009). Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 113:2637–45
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int. 27:1911–29
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, et al. (2005). Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 106:1042–7
   PubMed Web of Science ®Google Scholar
• Relogio A, Thomas P, Medina-Perez P, et al. (2014). Ras-mediated deregulation of the circadian clock in cancer. PLoS Genet. 10:e1004338
   PubMed Web of Science ®Google Scholar
• Sallam H, El-Serafi I, Meijer L, Hassan M. (2013). Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor-CR8- in mice. BMC Pharmacol Toxicol. 14:50
   Web of Science ®Google Scholar
• Sallam H, Jimenez P, Song H, et al. (2008). Age-dependent pharmacokinetics and effect of roscovitine on Cdk5 and Erk1/2 in the rat brain. Pharmacol Res. 58:32–7
   PubMed Web of Science ®Google Scholar
• Vita M, Abdel-Rehim M, Nilsson C, et al. (2005). Stability, pKa and plasma protein binding of roscovitine. J Chromatogr B Analyt Technol Biomed Life Sci. 821:75–80
   PubMed Web of Science ®Google Scholar
• Vita M, Meurling L, Pettersson T, et al. (2004). Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: Pharmacokinetics of roscovitine in rat. J Pharm Biomed Anal. 34:425–31
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu Q, Leskov KS, et al. (2013). Roscovitine suppresses CD4 + T cells and T cell-mediated experimental uveitis. PLoS One. 8:e81154
   PubMed Web of Science ®Google Scholar